Annual Statements Open main menu

Alkermes plc. - Quarter Report: 2022 June (Form 10-Q)

 

 

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2022

 

OR

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number 001-35299

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

 

Ireland

 

98-1007018

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

Connaught House

1 Burlington Road

Dublin 4, Ireland, D04 C5Y6

(Address of principal executive offices)

 

+ 353-1-772-8000

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary shares, $0.01 par value

 

ALKS

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

 

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

 

The number of the registrant’s ordinary shares, $0.01 par value, outstanding as of July 22, 2022 was 164,254,275 shares.

 

 

 

 

 

 


 

 

ALKERMES PLC AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022

 

 

 

 

 

Page No.

PART I - FINANCIAL INFORMATION

 

Item 1.

Condensed Consolidated Financial Statements (unaudited):

 

 

Condensed Consolidated Balance Sheets — June 30, 2022 and December 31, 2021

5

 

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income — For the Three and Six Months Ended June 30, 2022 and 2021

6

 

Condensed Consolidated Statements of Cash Flows — For the Six Months Ended June 30, 2022 and 2021

7

 

Condensed Consolidated Statements of Shareholders’ Equity — For the Three and Six Months Ended June 30, 2022 and 2021

8

 

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

37

Item 4.

Controls and Procedures

37

 

 

PART II - OTHER INFORMATION

 

Item 1.

Legal Proceedings

38

Item 1A.

Risk Factors

38

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

38

Item 5.

Other Information

38

Item 6.

Exhibits

39

Signatures

40

 

2


 

 

Cautionary Note Concerning Forward-Looking Statements

This document contains and incorporates by reference “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, these statements can be identified by the use of forward-looking terminology such as “may,” “will,” “could,” “should,” “would,” “expect,” “anticipate,” “continue,” “believe,” “plan,” “estimate,” “intend,” or other similar words. These statements discuss future expectations and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward-looking information. Forward‑looking statements in this Quarterly Report on Form 10-Q (this “Form 10-Q”) may include, without limitation, statements regarding:

 

our expectations regarding our financial performance, including revenues, expenses, liquidity, capital expenditures and income taxes;

 

our expectations regarding our products, including expectations related to product development; regulatory filings, approvals and timelines; therapeutic and commercial value, scope and potential; and the costs and expenses related to such activities and expectations;

 

our expectations regarding the initiation, timing and results of clinical trials of our products;

 

our expectations regarding the competitive, payer, legislative, regulatory and policy landscape, and changes therein, related to our products, including competition from generic forms of our products or competitive products and development programs; barriers to access or coverage of our products and potential changes in reimbursement of our products; and legislation, regulations, executive orders, guidance or other measures that may impact pricing and reimbursement of, and access to, our products;

 

our expectations regarding the financial impact of currency exchange rate fluctuations and valuations;

 

our expectations regarding future amortization of intangible assets;

 

our expectations regarding collaborations, licensing arrangements and other significant agreements with third parties relating to our products and our development programs;

 

our expectations regarding the impact of new legislation, rules and regulations and the adoption of new accounting pronouncements;

 

our expectations regarding near‑term changes in the nature of our market risk exposures or in our management’s objectives and strategies with respect to managing such exposures;

 

our expectations regarding our ability to comply with restrictive covenants of our indebtedness and our ability to fund our debt service obligations;

 

our expectations regarding future capital requirements and expenditures for our operations and our ability to finance such capital requirements and expenditures;

 

our expectations regarding the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our products and intellectual property (“IP”), including our patents;

 

our expectations regarding the impact of the ongoing novel coronavirus (“COVID-19”) pandemic on our business and operations; and

 

other expectations discussed elsewhere in this Form 10-Q.

Actual results might differ materially from those expressed or implied by these forward-looking statements because these forward-looking statements are subject to risks, assumptions and uncertainties. In light of these risks, assumptions and uncertainties, the forward-looking expectations discussed in this Form 10-Q might not occur. You are cautioned not to place undue reliance on the forward-looking statements in this Form 10-Q, which speak only as of the date of this Form 10-Q. All subsequent written and oral forward-looking statements concerning the matters addressed in this Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except as required by applicable law or regulation, we do not undertake any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For information about the risks, assumptions and uncertainties of our business, see “Part I, Item 1A—Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, filed

3


 

with the United States (“U.S.”) Securities and Exchange Commission (the “SEC”) on February 16, 2022, as amended by our Amendment No. 1 to Annual Report on Form 10-K/A, filed with the SEC on April 29, 2022 (our “Annual Report”).

This Form 10-Q may include data that we obtained from industry publications and third-party research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that any industry publications and third-party research, surveys and studies from which data is included in this Form 10-Q are reliable, we have not independently verified any such data. This Form 10-Q may also include data based on our own internal estimates and research. Our internal estimates and research have not been verified by any independent source and are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Part I, Item 1A—Risk Factors” in our Annual Report. These and other factors could cause our results to differ materially from those expressed or implied in this Form 10-Q.

Note Regarding Company and Product References

Alkermes plc is a fully-integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. We have a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Use of terms such as “us,” “we,” “our,” “Alkermes” or the “Company” in this Form 10-Q is meant to refer to Alkermes plc and its consolidated subsidiaries. Except as otherwise suggested by the context, (a) references to “products” or “our products” in this Form 10-Q include our marketed products, marketed products using our proprietary technologies, our licensed products, our product candidates and product candidates using our proprietary technologies, (b) references to the “biopharmaceutical industry” in this Form 10-Q are intended to include reference to the “biotechnology industry” and/or the “pharmaceutical industry” and (c) references to “licensees” in this Form 10-Q are used interchangeably with references to “partners.”

Note Regarding Trademarks

We are the owner of various U.S. federal trademark registrations (“®”) and other trademarks (“TM”), including ALKERMES®, ARISTADA®, ARISTADA INITIO®, LinkeRx®, LYBALVI®, NanoCrystal® and VIVITROL®.

The following are trademarks of the respective companies listed: ANJESO®—Baudax Bio, Inc.; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA®, XEPLION®, and RISPERDAL CONSTA®—Johnson & Johnson Corporation (or its affiliates); KEYTRUDA®—Merck Sharp & Dohme Corp.; and VUMERITY®—Biogen MA Inc. (together with its affiliates, “Biogen”). Other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Form 10-Q may be referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

4


 

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements:

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

 

 

 

June 30, 2022

 

December 31, 2021

 

 

(In thousands, except share and per share amounts)

ASSETS

 

 

 

 

CURRENT ASSETS:

 

 

 

 

Cash and cash equivalents

 

$254,646

 

$337,544

Receivables, net

 

245,840

 

313,193

Investments—short-term

 

326,321

 

198,767

Inventory

 

155,608

 

150,335

Contract assets

 

16,486

 

13,363

Prepaid expenses and other current assets

 

47,090

 

48,967

Total current assets

 

1,045,991

 

1,062,169

PROPERTY, PLANT AND EQUIPMENT, NET

 

337,146

 

341,054

INVESTMENTS—LONG-TERM

 

179,010

 

229,430

RIGHT-OF-USE ASSETS

 

111,119

 

115,627

INTANGIBLE ASSETS, NET

 

56,011

 

74,043

GOODWILL

 

92,873

 

92,873

DEFERRED TAX ASSETS

 

123,702

 

81,833

OTHER ASSETS

 

11,565

 

27,455

TOTAL ASSETS

 

$1,957,417

 

$2,024,484

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

Accounts payable and accrued expenses

 

$186,814

 

$208,491

Accrued sales discounts, allowances and reserves

 

228,973

 

237,216

Operating lease liabilities—short-term

 

15,944

 

16,240

Contract liabilities—short-term

 

3,787

 

6,339

Current portion of long-term debt

 

3,000

 

3,000

Total current liabilities

 

438,518

 

471,286

LONG-TERM DEBT

 

291,537

 

292,804

OPERATING LEASE LIABILITIES—LONG-TERM

 

99,832

 

104,162

OTHER LONG-TERM LIABILITIES

 

45,206

 

43,648

Total liabilities

 

875,093

 

911,900

COMMITMENTS AND CONTINGENT LIABILITIES (Note 15)

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at June 30, 2022 and December 31, 2021, respectively

 

 

Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 168,782,701 and 165,790,549 shares issued; 164,232,704 and 161,937,327 shares outstanding at June 30, 2022 and December 31, 2021, respectively

 

1,688

 

1,658

Treasury shares, at cost (4,549,997 and 3,853,222 shares at June 30, 2022 and December 31, 2021, respectively)

 

(160,241)

 

(142,658)

Additional paid-in capital

 

2,858,422

 

2,798,325

Accumulated other comprehensive loss

 

(10,488)

 

(3,723)

Accumulated deficit

 

(1,607,057)

 

(1,541,018)

Total shareholders’ equity

 

1,082,324

 

1,112,584

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$1,957,417

 

$2,024,484

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5


 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

(In thousands, except per share amounts)

 

REVENUES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

190,787

 

 

$

160,808

 

 

$

362,055

 

 

$

290,771

 

Manufacturing and royalty revenues

 

 

85,326

 

 

 

142,294

 

 

 

190,496

 

 

 

262,141

 

License revenue

 

 

 

 

 

 

 

 

2,000

 

 

 

1,500

 

Research and development revenue

 

 

106

 

 

 

615

 

 

 

213

 

 

 

735

 

Total revenues

 

 

276,219

 

 

 

303,717

 

 

 

554,764

 

 

 

555,147

 

EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)

 

 

58,360

 

 

 

53,124

 

 

 

113,519

 

 

 

94,144

 

Research and development

 

 

92,873

 

 

 

97,473

 

 

 

188,826

 

 

 

189,741

 

Selling, general and administrative

 

 

150,377

 

 

 

139,188

 

 

 

295,429

 

 

 

264,356

 

Amortization of acquired intangible assets

 

 

9,066

 

 

 

9,511

 

 

 

18,032

 

 

 

18,917

 

Total expenses

 

 

310,676

 

 

 

299,296

 

 

 

615,806

 

 

 

567,158

 

OPERATING (LOSS) INCOME

 

 

(34,457

)

 

 

4,421

 

 

 

(61,042

)

 

 

(12,011

)

OTHER (EXPENSE) INCOME, NET:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

896

 

 

 

623

 

 

 

1,469

 

 

 

1,487

 

Interest expense

 

 

(2,369

)

 

 

(2,407

)

 

 

(4,719

)

 

 

(6,377

)

Change in the fair value of contingent consideration

 

 

870

 

 

 

3,240

 

 

 

(18,197

)

 

 

4,518

 

Other income (expense), net

 

 

1,810

 

 

 

(222

)

 

 

4,241

 

 

 

(615

)

Total other (expense) income, net

 

 

1,207

 

 

 

1,234

 

 

 

(17,206

)

 

 

(987

)

(LOSS) EARNINGS BEFORE INCOME TAXES

 

 

(33,250

)

 

 

5,655

 

 

 

(78,248

)

 

 

(12,998

)

INCOME TAX (BENEFIT) PROVISION

 

 

(3,114

)

 

 

3,291

 

 

 

(12,209

)

 

 

7,056

 

NET (LOSS) INCOME

 

$

(30,136

)

 

$

2,364

 

 

$

(66,039

)

 

$

(20,054

)

(LOSS) EARNINGS PER ORDINARY SHARE:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.18

)

 

$

0.01

 

 

$

(0.40

)

 

$

(0.13

)

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

163,839

 

 

 

160,817

 

 

 

163,165

 

 

 

160,229

 

Diluted

 

 

163,839

 

 

 

163,937

 

 

 

163,165

 

 

 

160,229

 

COMPREHENSIVE (LOSS) INCOME:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

$

(30,136

)

 

$

2,364

 

 

$

(66,039

)

 

$

(20,054

)

Holding loss, net of a tax (benefit) provision of $326, $(79), $(1,055) and $(253), respectively

 

 

(2,254

)

 

 

(272

)

 

 

(6,765

)

 

 

(873

)

COMPREHENSIVE (LOSS) INCOME

 

$

(32,390

)

 

$

2,092

 

 

$

(72,804

)

 

$

(20,927

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6


 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2022

 

 

2021

 

 

 

(In thousands)

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(66,039

)

 

$

(20,054

)

Adjustments to reconcile net loss to cash flows from operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

38,588

 

 

 

38,119

 

Share-based compensation expense

 

 

41,720

 

 

 

43,003

 

Deferred income taxes

 

 

(40,815

)

 

 

10,806

 

Change in the fair value of contingent consideration

 

 

18,197

 

 

 

(4,518

)

Loss on debt extinguishment

 

 

 

 

 

171

 

Other non-cash charges

 

 

637

 

 

 

1,302

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Receivables

 

 

67,382

 

 

 

(22,194

)

Contract assets

 

 

(3,123

)

 

 

5,607

 

Inventory

 

 

(4,569

)

 

 

(11,232

)

Prepaid expenses and other assets

 

 

(1,986

)

 

 

2,029

 

Right-of-use assets

 

 

8,331

 

 

 

8,595

 

Accounts payable and accrued expenses

 

 

(29,045

)

 

 

(52,629

)

Contract liabilities

 

 

(4,071

)

 

 

(3,108

)

Operating lease liabilities

 

 

(8,911

)

 

 

(7,821

)

Other long-term liabilities

 

 

3,076

 

 

 

(159

)

Cash flows provided by (used in) operating activities

 

 

19,372

 

 

 

(12,083

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Additions of property, plant and equipment

 

 

(17,753

)

 

 

(14,546

)

Proceeds from the sale of equipment

 

 

 

 

 

177

 

Proceeds from contingent consideration

 

 

1,043

 

 

 

7,889

 

Return of Fountain Healthcare Partners II, L.P. investment

 

 

485

 

 

 

 

Payment made for licensed Intellectual Property ("IP")

 

 

 

 

 

(1,000

)

Purchases of investments

 

 

(194,879

)

 

 

(201,774

)

Sales and maturities of investments

 

 

109,925

 

 

 

175,499

 

Cash flows used in investing activities

 

 

(101,179

)

 

 

(33,755

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from the issuance of ordinary shares under share-based compensation arrangements

 

 

17,992

 

 

 

20,498

 

Employee taxes paid related to net share settlement of equity awards

 

 

(17,583

)

 

 

(11,120

)

Proceeds from the issuance of long-term debt

 

 

 

 

 

23,567

 

Payment made for debt extinguishment

 

 

 

 

 

(977

)

Principal payments of long-term debt

 

 

(1,500

)

 

 

(750

)

Cash flows (used in) provided by financing activities

 

 

(1,091

)

 

 

31,218

 

NET DECREASE IN CASH AND CASH EQUIVALENTS

 

 

(82,898

)

 

 

(14,620

)

CASH AND CASH EQUIVALENTS—Beginning of period

 

 

337,544

 

 

 

272,961

 

CASH AND CASH EQUIVALENTS—End of period

 

$

254,646

 

 

$

258,341

 

SUPPLEMENTAL CASH FLOW DISCLOSURE:

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Purchased capital expenditures included in accounts payable and accrued expenses

 

$

4,863

 

 

$

1,023

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

7


 

 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ordinary Shares

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Treasury Stock

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Shares

 

 

Amount

 

 

Total

 

 

 

(In thousands, except share data)

 

BALANCE — December 31, 2021

 

 

165,790,549

 

 

$

1,658

 

 

$

2,798,325

 

 

$

(3,723

)

 

$

(1,541,018

)

 

 

(3,853,222

)

 

$

(142,658

)

 

$

1,112,584

 

Issuance of ordinary shares under employee stock plans

 

 

1,953,293

 

 

 

19

 

 

 

1,776

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,795

 

Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(678,209

)

 

 

(17,069

)

 

 

(17,069

)

Share-based compensation

 

 

 

 

 

 

 

 

18,494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

18,494

 

Unrealized loss on marketable securities, net of tax (benefit) of $(1,382)

 

 

 

 

 

 

 

 

 

 

 

(4,511

)

 

 

 

 

 

 

 

 

 

 

 

(4,511

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(35,903

)

 

 

 

 

 

 

 

 

(35,903

)

BALANCE — March 31, 2022

 

 

167,743,842

 

 

$

1,677

 

 

$

2,818,595

 

 

$

(8,234

)

 

$

(1,576,921

)

 

 

(4,531,431

)

 

$

(159,727

)

 

$

1,075,390

 

Issuance of ordinary shares under employee stock plans

 

 

1,038,859

 

 

 

11

 

 

 

16,186

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

16,197

 

Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(18,566

)

 

 

(514

)

 

 

(514

)

Share-based compensation

 

 

 

 

 

 

 

 

23,641

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23,641

 

Unrealized loss on marketable securities, net of tax provision of $326

 

 

 

 

 

 

 

 

 

 

 

(2,254

)

 

 

 

 

 

 

 

 

 

 

 

(2,254

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(30,136

)

 

 

 

 

 

 

 

 

(30,136

)

BALANCE — June 30, 2022

 

 

168,782,701

 

 

$

1,688

 

 

$

2,858,422

 

 

$

(10,488

)

 

$

(1,607,057

)

 

 

(4,549,997

)

 

$

(160,241

)

 

$

1,082,324

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

8


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ordinary Shares

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Treasury Stock

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Shares

 

 

Amount

 

 

Total

 

 

 

(In thousands, except share data)

 

BALANCE — December 31, 2020

 

 

162,269,220

 

 

$

1,620

 

 

$

2,685,647

 

 

$

(1,349

)

 

$

(1,492,849

)

 

 

(3,108,079

)

 

$

(126,087

)

 

$

1,066,982

 

Issuance of ordinary shares under employee stock plans

 

 

1,566,685

 

 

18

 

 

 

2,035

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,053

 

Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(529,817

)

 

 

(10,413

)

 

 

(10,413

)

Share-based compensation

 

 

 

 

 

 

 

 

15,552

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15,552

 

Unrealized loss on marketable securities, net of tax (benefit) of $(174)

 

 

 

 

 

 

 

 

 

 

 

(601

)

 

 

 

 

 

 

 

 

 

 

 

(601

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(22,418

)

 

 

 

 

 

 

 

 

(22,418

)

BALANCE — March 31, 2021

 

 

163,835,905

 

 

$

1,638

 

 

$

2,703,234

 

 

$

(1,950

)

 

$

(1,515,267

)

 

 

(3,637,896

)

 

$

(136,500

)

 

$

1,051,155

 

Issuance of ordinary shares under employee stock plans

 

 

1,129,869

 

 

12

 

 

 

18,433

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

18,445

 

Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(31,752

)

 

 

(707

)

 

 

(707

)

Share-based compensation

 

 

 

 

 

 

 

 

26,917

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

26,917

 

Unrealized loss on marketable securities, net of tax (benefit) of $(79)

 

 

 

 

 

 

 

 

 

 

 

(272

)

 

 

 

 

 

 

 

 

 

 

 

(272

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,364

 

 

 

 

 

 

 

 

 

2,364

 

BALANCE — June 30, 2021

 

 

164,965,774

 

 

$

1,650

 

 

$

2,748,584

 

 

$

(2,222

)

 

$

(1,512,903

)

 

 

(3,669,648

)

 

$

(137,207

)

 

$

1,097,902

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

9


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited)

 

 

1. THE COMPANY

Alkermes plc is a fully-integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Alkermes has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, the Company has a research and development (“R&D”) center in Waltham, Massachusetts; an R&D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements of the Company for the three and six months ended June 30, 2022 and 2021 are unaudited and have been prepared on a basis substantially consistent with the audited financial statements for the year ended December 31, 2021. The year-end condensed consolidated balance sheet data, which is presented for comparative purposes, was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. (commonly referred to as “GAAP”). In the opinion of management, the condensed consolidated financial statements include all adjustments of a normal recurring nature that are necessary to state fairly the results of operations for the reported periods.

These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto of the Company, which are contained in the Company’s Annual Report. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for any full fiscal year.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries as disclosed in Note 2, Summary of Significant Accounting Policies, in the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report. Intercompany accounts and transactions have been eliminated.

Reclassification

The Company reclassified certain prior year amounts on the condensed consolidated balance sheet to conform to the current year presentation. These reclassifications had no impact on the previously reported total assets, liabilities or shareholders’ equity.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies, including, but not limited to, those related to revenue from contracts with its customers and related allowances, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments, contingent consideration and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different conditions or using different assumptions.

10


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

Segment Information

The Company operates as one business segment, which is the business of developing, manufacturing and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. The Company’s chief decision maker, its Chief Executive Officer and chairman of its board of directors, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit.

Risks and Uncertainties

In March 2020, COVID-19 was declared a global pandemic by the World Health Organization. To date, COVID-19 has surfaced in nearly all regions around the world and resulted in travel restrictions and business slowdowns and/or shutdowns in affected areas. Ireland, all U.S. states, and many local jurisdictions and countries around the world have, at times during the pandemic, issued and implemented quarantines, vaccine and masking mandates, restrictive executive orders and other similar government orders, restrictions, and recommendations for their residents to help control the spread of COVID-19, and may continue to do so while the pandemic persists. Such orders, mandates, restrictions and/or recommendations, and/or the perception that additional orders, mandates, restrictions or recommendations could occur, have, at times during the pandemic, resulted in widespread interruptions and closures of businesses, including healthcare systems that serve people living with addiction and serious mental illness, work stoppages, slowdowns and/or delays, remote work policies and travel restrictions, among other effects.

The COVID-19 pandemic has caused, and the Company expects may continue to cause, varying degrees of disruption to its employees and its business operations. While the Company has continued to operate its manufacturing facilities and supply its medicines throughout the pandemic, it has at times during the pandemic experienced labor or supply chain disruptions at its manufacturing facilities, and may continue to experience such disruptions while the pandemic persists. In addition, while the Company has continued to conduct R&D activities, including its ongoing clinical trials, the COVID-19 pandemic has at times impacted the timelines of certain of its early-stage discovery efforts and clinical trials, and may continue to impact such timelines while the pandemic persists. The Company works with its internal teams, its clinical investigators, R&D vendors and critical supply chain vendors to continually assess, and mitigate, the potential impact of COVID-19 on its manufacturing operations and R&D activities.

A number of the marketed products from which the Company derives revenue, including manufacturing and royalty revenue, are injectable medications administered by healthcare professionals. Given developments that have transpired to date, and may continue to transpire, in response to the pandemic, including business closures, travel restrictions, quarantine, testing and/or vaccine mandates and other protocols, labor shortages, and other restrictive measures, commercial sales of these marketed products have been adversely impacted to varying degrees during the pandemic and may continue to be adversely impacted while the pandemic persists.

In addition, the Company relies upon third parties for many aspects of its business, including the provision of goods and services related to the manufacture of its clinical products and its and its partners’ marketed products, the conduct of its clinical trials, and the sale of its proprietary marketed products and the marketed products of its licensees from which the Company receives manufacturing and royalty revenue. Any prolonged material disruption to the third parties on which the Company relies could negatively impact the Company’s ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Company’s business, results of operations and financial condition.

Due to numerous uncertainties surrounding the ongoing COVID-19 pandemic, the actual impact of the pandemic on the Company’s financial condition and operating results may differ from its current projections. These uncertainties include, among other things, the ultimate severity and duration of the pandemic and the manner in which it continues to evolve, including the emergence, prevalence and severity of new or existing COVID-19 variants, and future developments in response thereto, which are highly uncertain and cannot be predicted as of the date of this Form 10-Q.

11


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

3. REVENUE FROM CONTRACTS WITH CUSTOMERS

 

Product Sales, Net

The Company’s product sales, net consist of sales in the U.S. of VIVITROL, ARISTADA and ARISTADA INITIO and, following its commercial launch in October 2021, LYBALVI, primarily to wholesalers, specialty distributors and pharmacies. During the three and six months ended June 30, 2022 and 2021, the Company recorded product sales, net, as follows:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

(In thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

VIVITROL

 

$

96,105

 

 

$

88,417

 

 

$

180,959

 

 

$

162,951

 

ARISTADA and ARISTADA INITIO

 

 

74,622

 

 

 

72,391

 

 

 

147,107

 

 

 

127,820

 

LYBALVI

 

 

20,060

 

 

 

 

 

 

33,989

 

 

 

 

Total product sales, net

 

$

190,787

 

 

$

160,808

 

 

$

362,055

 

 

$

290,771

 

 

Manufacturing and Royalty Revenues

During the three and six months ended June 30, 2022 and 2021, the Company recorded manufacturing and royalty revenues as follows:

 

 

 

Three Months Ended June 30, 2022

 

 

Six Months Ended June 30, 2022

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

Long-acting INVEGA products(1)

 

$

 

 

$

26,648

 

 

$

26,648

 

 

$

 

 

$

63,702

 

 

$

63,702

 

VUMERITY

 

 

5,650

 

 

 

20,520

 

 

 

26,170

 

 

 

17,045

 

 

 

39,720

 

 

 

56,765

 

RISPERDAL CONSTA

 

 

8,571

 

 

 

1,820

 

 

 

10,391

 

 

 

24,149

 

 

 

3,668

 

 

 

27,817

 

Other

 

 

11,353

 

 

 

10,764

 

 

 

22,117

 

 

 

23,207

 

 

 

19,005

 

 

 

42,212

 

 

 

$

25,574

 

 

$

59,752

 

 

$

85,326

 

 

$

64,401

 

 

$

126,095

 

 

$

190,496

 

 

 

 

Three Months Ended June 30, 2021

 

 

Six Months Ended June 30, 2021

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

Long-acting INVEGA products(1)

 

$

 

 

$

81,072

 

 

$

81,072

 

 

$

 

 

$

142,642

 

 

$

142,642

 

VUMERITY

 

 

6,724

 

 

 

13,624

 

 

 

20,348

 

 

 

9,172

 

 

 

24,616

 

 

 

33,788

 

RISPERDAL CONSTA

 

 

12,003

 

 

 

2,448

 

 

 

14,451

 

 

 

22,686

 

 

 

5,927

 

 

 

28,613

 

Other

 

 

10,566

 

 

 

15,857

 

 

 

26,423

 

 

 

22,520

 

 

 

34,578

 

 

 

57,098

 

 

 

$

29,293

 

 

$

113,001

 

 

$

142,294

 

 

$

54,378

 

 

$

207,763

 

 

$

262,141

 

 

 

(1)

“Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate)  

In November 2021, the Company received notice of partial termination of its license agreement with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson Corporation (“Janssen Pharmaceutica”) in respect of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA, pursuant to which Janssen Pharmaceutica received access and rights to Alkermes’ small particle pharmaceutical compound technology, known as NanoCrystal Technology. When the partial termination became effective in February 2022, Janssen Pharmaceutica ceased paying royalties related to sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA in the U.S. and the Company stopped recognizing royalty revenue related to net sales of these products in the U.S. In April 2022, the Company commenced binding arbitration proceedings related to, among other things, Janssen Pharmaceutica’s partial termination of the license agreement and Janssen Pharmaceutica’s royalty and other obligations under the agreement. Refer to Note 15, Commitments and Contingencies within the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for additional information regarding the arbitration proceedings with Janssen Pharmaceutica.

12


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

Contract Assets

Contract assets include unbilled amounts resulting from sales under certain of the Company’s manufacturing contracts where revenue is recognized over time and $5.0 million of expected consideration from the Company’s collaboration with Biogen related to VUMERITY. The amounts included in the contract assets table below are classified as “Current assets” in the accompanying condensed consolidated balance sheets, as they relate to manufacturing processes that are completed in ten days to eight weeks and, in the case of the $5.0 million of consideration, an amount that is expected to be received in November 2022.

Total contract assets at June 30, 2022 were as follows:

 

(In thousands)

 

Contract Assets

 

Contract assets at December 31, 2021

 

$

13,363

 

Additions

 

 

21,883

 

Transferred to receivables, net

 

 

(18,760

)

Contract assets at June 30, 2022

 

$

16,486

 

 

Contract Liabilities

 

Contract liabilities consist of contractual obligations related to deferred revenue. At June 30, 2022 and December 31, 2021, $3.8 million and $6.3 million of the contract liabilities, respectively, were classified as “Contract liabilities–short-term” in the accompanying condensed consolidated balance sheets and $10.0 million and $11.5 million of the contract liabilities, respectively, were classified as “Other long-term liabilities” in the accompanying condensed consolidated balance sheets.

Total contract liabilities at June 30, 2022 were as follows:

 

(In thousands)

 

Contract Liabilities

 

Contract liabilities at December 31, 2021

 

$

17,830

 

Additions

 

 

829

 

Amounts recognized into revenue

 

 

(4,900

)

Contract liabilities at June 30, 2022

 

$

13,759

 

 

13


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

4. INVESTMENTS

Investments consisted of the following (in thousands):

 

 

 

 

 

 

 

Gross Unrealized

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Losses

 

 

 

 

 

 

 

Amortized

 

 

 

 

 

 

Less than

 

 

Greater than

 

 

Estimated

 

June 30, 2022

 

Cost

 

 

Gains

 

 

One Year

 

 

One Year

 

 

Fair Value

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

146,785

 

 

$

4

 

 

$

(1,744

)

 

$

 

 

$

145,045

 

U.S. government and agency debt securities

 

 

117,944

 

 

 

22

 

 

 

(909

)

 

 

 

 

 

117,057

 

Non-U.S. government debt securities

 

 

64,786

 

 

 

 

 

 

(504

)

 

 

(63

)

 

 

64,219

 

Total short-term investments

 

 

329,515

 

 

 

26

 

 

 

(3,157

)

 

 

(63

)

 

 

326,321

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

94,346

 

 

 

 

 

 

(2,806

)

 

 

(48

)

 

 

91,492

 

U.S. government and agency debt securities

 

 

73,000

 

 

 

 

 

 

(2,364

)

 

 

(50

)

 

 

70,586

 

Non-U.S. government debt securities

 

 

15,679

 

 

 

 

 

 

(393

)

 

 

(174

)

 

 

15,112

 

 

 

 

183,025

 

 

 

 

 

 

(5,563

)

 

 

(272

)

 

 

177,190

 

Held-to-maturity securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Certificates of deposit

 

 

1,820

 

 

 

 

 

 

 

 

 

 

 

 

1,820

 

Total long-term investments

 

 

184,845

 

 

 

 

 

 

(5,563

)

 

 

(272

)

 

 

179,010

 

Total investments

 

$

514,360

 

 

$

26

 

 

$

(8,720

)

 

$

(335

)

 

$

505,331

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

85,201

 

 

$

177

 

 

$

(39

)

 

$

 

 

$

85,339

 

U.S. government and agency debt securities

 

 

45,349

 

 

 

35

 

 

 

(24

)

 

 

 

 

 

45,360

 

Non-U.S. government debt securities

 

 

68,046

 

 

 

75

 

 

 

(53

)

 

 

 

 

 

68,068

 

Total short-term investments

 

 

198,596

 

 

 

287

 

 

 

(116

)

 

 

 

 

 

198,767

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

111,793

 

 

 

 

 

 

(654

)

 

 

 

 

 

111,139

 

U.S. government and agency debt securities

 

 

81,296

 

 

 

 

 

 

(517

)

 

 

 

 

 

80,779

 

Non-U.S. government debt securities

 

 

35,902

 

 

 

 

 

 

(210

)

 

 

 

 

 

35,692

 

 

 

 

228,991

 

 

 

 

 

 

(1,381

)

 

 

 

 

 

227,610

 

Held-to-maturity securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Certificates of deposit

 

 

1,820

 

 

 

 

 

 

 

 

 

 

 

 

1,820

 

Total long-term investments

 

 

230,811

 

 

 

 

 

 

(1,381

)

 

 

 

 

 

229,430

 

Total investments

 

$

429,407

 

 

$

287

 

 

$

(1,497

)

 

$

 

 

$

428,197

 

 

At June 30, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. Investments with unrealized losses consisted primarily of corporate debt securities and debt securities issued and backed by U.S. agencies and the U.S. government. At June 30, 2022, the aggregate estimated fair value of investments in an unrealized loss position was $492.1 million. The Company has the intent and ability to hold these investments until recovery, which may be at maturity. In making the determination whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. During the three months ended June 30, 2021, the Company determined there was an other-than-temporary loss of $0.9 million that was recorded within “Other income (expense), net” in the accompanying condensed consolidated statements of operations and comprehensive (loss) income.

 

In January 2022, the Company purchased a convertible promissory note in the principal amount of $0.5 million from Synchronicity Pharma, Inc. (“Synchronicity”), a related party, that matures on the earlier of September 30, 2022, the closing of a preferred equity financing, the closing of a merger, business combination or sale of stock resulting in

14


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

Synchronicity’s stockholders owning less than 50% of the surviving entity, or an event of default. The convertible promissory note was classified as an available-for-sale corporate debt instrument.

 

In May 2014, the Company entered into an agreement to invest in a partnership, Fountain Healthcare Partners II, L.P. of Ireland (“Fountain”), which was created to carry on the business of investing exclusively in companies and businesses engaged in the healthcare, pharmaceutical and life sciences sectors. As of June 30, 2022, the Company’s total contribution in Fountain was equal to €8.0 million, and its commitment represented approximately 7% of the partnership’s total funding. The Company is accounting for its investment in Fountain under the equity method.

 

During the three months ended March 31, 2022, one of the companies within the Fountain portfolio was acquired by a third party. The Company’s proportional share of the proceeds from this transaction was $1.1 million, of which $1.0 million was received during the three months ended March 31, 2022 and the remaining $0.1 million is being held in escrow until May 2023. The transaction was accounted for under the cumulative earnings approach whereby the return on investment of $0.6 million was recorded as a gain within “Other income (expense), net” in the accompanying condensed consolidated statements of operations and comprehensive (loss) income and the return of investment of $0.5 million was recorded as a reduction in the Company’s net investment in Fountain. The Company’s net investment in Fountain was $6.7 million and $6.1 million at June 30, 2022 and December 31, 2021, respectively, and was included within “Other assets” in the accompanying condensed consolidated balance sheets.

 

During the three and six months ended June 30, 2022, the Company recorded an increase of $1.1 million in its investment in Fountain, which represented the Company’s proportional share of Fountain’s net gains.

 

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:

 

 

 

Six Months Ended June 30,

 

(In thousands)

 

2022

 

 

2021

 

Proceeds from the sales and maturities of investments

 

$

109,925

 

 

$

175,499

 

Realized gains

 

$

 

 

$

 

Realized losses

 

$

 

 

$

977

 

 

The Company’s available-for-sale and held-to-maturity securities at June 30, 2022 had contractual maturities in the following periods:

 

 

 

Available-for-sale

 

 

Held-to-maturity

 

 

 

Amortized

 

 

Estimated

 

 

Amortized

 

 

Estimated

 

(In thousands)

 

Cost

 

 

Fair Value

 

 

Cost

 

 

Fair Value

 

Within 1 year

 

$

326,560

 

 

$

323,341

 

 

$

1,820

 

 

$

1,820

 

After 1 year through 5 years

 

 

185,980

 

 

 

180,170

 

 

 

 

 

 

 

Total

 

$

512,540

 

 

$

503,511

 

 

$

1,820

 

 

$

1,820

 

 

5. FAIR VALUE

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation techniques that the Company utilized to determine such fair value:

 

 

 

June 30,

 

 

 

 

 

 

 

 

 

 

 

 

 

(In thousands)

 

2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

14,980

 

 

$

14,980

 

 

$

 

 

$

 

U.S. government and agency debt securities

 

 

187,643

 

 

 

153,482

 

 

 

34,161

 

 

 

 

Corporate debt securities

 

 

236,537

 

 

 

 

 

 

236,037

 

 

 

500

 

Non-U.S. government debt securities

 

 

79,331

 

 

 

 

 

 

79,331

 

 

 

 

Contingent consideration

 

 

3,779

 

 

 

 

 

 

 

 

 

3,779

 

Total

 

$

522,270

 

 

$

168,462

 

 

$

349,529

 

 

$

4,279

 

 

15


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

 

 

December 31,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2021

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government and agency debt securities

 

$

126,139

 

 

$

96,597

 

 

$

29,542

 

 

$

 

Corporate debt securities

 

 

196,478

 

 

 

 

 

 

196,478

 

 

 

 

Non-U.S. government debt securities

 

 

103,760

 

 

 

 

 

 

103,760

 

 

 

 

Contingent consideration

 

 

23,048

 

 

 

 

 

 

 

 

 

23,048

 

Total

 

$

449,425

 

 

$

96,597

 

 

$

329,780

 

 

$

23,048

 

 

The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period.

There were no transfers of any securities between levels during the six months ended June 30, 2022. The following table is a rollforward of the fair value of the Company’s investments with fair values that were determined using Level 3 inputs at June 30, 2022:

 

(In thousands)

 

Fair Value

 

Balance, January 1, 2022

 

$

23,048

 

Purchase of corporate debt security

 

 

500

 

Change in the fair value of contingent consideration

 

 

(18,197

)

Milestone and royalty payments received by the Company related to contingent consideration

 

 

(1,043

)

Royalty payments due to the Company related to contingent consideration

 

 

(29

)

Balance, June 30, 2022

 

$

4,279

 

 

The Company’s investments in U.S. government and agency debt securities, non-U.S. government agency debt securities and corporate debt securities classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

In April 2015, the Company sold its Gainesville, GA manufacturing facility, the related manufacturing and royalty revenue associated with certain products manufactured at the facility, and the rights to intravenous/intramuscular (“IV/IM”) and parenteral forms of Meloxicam to Recro Pharma, Inc. (“Recro”) and Recro Gainesville LLC (such transaction, the “Gainesville Transaction”). The Gainesville Transaction included in the purchase price contingent consideration tied to low double digit royalties on net sales of the IV/IM and parenteral forms of Meloxicam and any other product with the same active ingredient as Meloxicam IV/IM that is discovered or identified using certain of the Company’s IP to which Recro was provided a right of use, through license or transfer, pursuant to the Gainesville Transaction (such products, the “Meloxicam Products”), and milestone payments upon the achievement of certain regulatory and sales milestones related to the Meloxicam Products.

In November 2019, Recro spun out its acute care segment to Baudax Bio, Inc. (“Baudax”), a publicly-traded pharmaceutical company. As part of this transaction, Recro’s obligations to pay certain contingent consideration from the Gainesville Transaction were assigned and/or transferred to Baudax.

At June 30, 2022, the Company determined the fair value of the contingent consideration to be received as follows:

 

As of December 31, 2021, the Company had received $7.8 million in milestone payments and was due to receive an additional $38.6 million related to the U.S. Food and Drug Administration (“FDA”) approval of the New Drug Application (“NDA”) for ANJESO. This amount is due in six equal, annual installments from March 2022 through March 2027. At June 30, 2022, Baudax had paid the Company $1.0 million of the $6.4 million payment that was due in March 2022;

 

The Company is entitled to receive future royalties on net sales of Meloxicam Products; and

16


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

 

The Company is entitled to receive payments of up to $80.0 million related to the achievement of certain sales milestones on future sales of the Meloxicam Products. At June 30, 2022, the Company did not believe it was probable that any of the sales milestones would be achieved.

In Baudax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2022, Baudax included disclosures regarding its ability to continue as a going concern and its March 2022 reduction in workforce by approximately 80%, which was designed to reduce its operational expenses and conserve its cash resources. In light of Baudax’s disclosures regarding its ability to continue as a going concern and the fact that, as of June 30, 2022, Baudax had paid $1.0 million of the $6.4 million that was due in March 2022, the Company has applied a 100% likelihood that Baudax would default on its obligations and applied a recovery rate of 9% based on an analysis performed by Standard and Poor’s regarding post-default recoveries. However, for avoidance of doubt, the Company has not waived its right to receive any portion of the payments owing by Baudax. For discussion on the calculation of the fair value of the contingent consideration at December 31, 2021, refer to Note 5, Fair Value within the “Notes to Consolidated Financial Statements” in the Annual Report.

At June 30, 2022 and December 31, 2021, the Company determined that the fair value of the contingent consideration was $3.8 million and $23.0 million, respectively. At June 30, 2022 and December 31, 2021, $3.8 million and $6.4 million, respectively, of the fair value of the contingent consideration was included within “Prepaid expenses and other current assets” in the accompanying condensed consolidated balance sheets, and none and $16.6 million, respectively, of the fair value of the contingent consideration was included within “Other assets” in the accompanying condensed consolidated balance sheets. Changes in the fair value of the contingent consideration are recorded within “Change in the fair value of contingent consideration” in the accompanying condensed consolidated statements of operations and comprehensive (loss) income.

The carrying amounts reflected in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term nature.

The estimated fair value of the Company’s long-term debt under its amended and restated credit agreement (such debt, the “2026 Term Loans”), which was based on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been, or will be, realized in the future, was $277.7 million and $285.8 million at June 30, 2022 and December 31, 2021, respectively.

6. INVENTORY

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Inventory consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2022

 

 

2021

 

Raw materials

 

$

52,870

 

 

$

56,125

 

Work in process

 

 

70,437

 

 

 

59,105

 

Finished goods(1)

 

 

32,301

 

 

 

35,105

 

Total inventory

 

$

155,608

 

 

$

150,335

 

 

 

(1)

At June 30, 2022 and December 31, 2021, the Company had $25.7 million and $25.1 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

17


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

7. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2022

 

 

2021

 

Land

 

$

6,560

 

 

$

6,560

 

Building and improvements

 

 

193,914

 

 

 

192,920

 

Furniture, fixtures and equipment

 

 

406,868

 

 

 

398,099

 

Leasehold improvements

 

 

52,526

 

 

 

52,526

 

Construction in progress

 

 

92,839

 

 

 

86,512

 

Subtotal

 

 

752,707

 

 

 

736,617

 

Less: accumulated depreciation

 

 

(415,561

)

 

 

(395,563

)

Total property, plant and equipment, net

 

$

337,146

 

 

$

341,054

 

 

8. GOODWILL AND INTANGIBLE ASSETS

 

Goodwill and intangible assets consisted of the following:

 

 

 

 

 

June 30, 2022

 

(In thousands)

 

Weighted Amortizable Life (Years)

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

 

Net Carrying Amount

 

Goodwill

 

 

 

$

92,873

 

 

$

 

 

$

92,873

 

Finite-lived intangible assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration agreements

 

12

 

$

465,590

 

 

$

(421,331

)

 

$

44,259

 

Capitalized IP

 

11-13

 

 

118,160

 

 

 

(106,408

)

 

 

11,752

 

Total

 

 

 

$

583,750

 

 

$

(527,739

)

 

$

56,011

 

 

Based on the Company’s most recent analysis, amortization of intangible assets included in the accompanying condensed consolidated balance sheet at June 30, 2022 is expected to be approximately $35.0 million, $35.0 million and $1.0 million in the years ending December 31, 2022 through 2024, respectively. Although the Company believes that such analysis, and the available information and assumptions underlying such analysis, are reasonable, given the inherent risks and uncertainties underlying its expectations regarding such future revenues, there is the potential for the Company’s actual results to vary significantly from such expectations. If revenues are projected to change, the related amortization of the intangible assets will change in proportion to the change in revenues.

 

9. LEASES

 

Future lease payments under non-cancelable leases at June 30, 2022 and December 31, 2021 consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2022

 

 

2021

 

2022

 

$

9,012

 

 

$

17,991

 

2023

 

 

18,206

 

 

 

17,329

 

2024

 

 

18,476

 

 

 

17,535

 

2025

 

 

18,750

 

 

 

17,808

 

2026

 

 

14,719

 

 

 

13,777

 

Thereafter

 

 

95,289

 

 

 

95,229

 

Total operating lease payments

 

$

174,452

 

 

$

179,669

 

Less: imputed interest

 

 

(58,676

)

 

 

(59,267

)

Total operating lease liabilities

 

$

115,776

 

 

$

120,402

 

 

At June 30, 2022, the weighted average incremental borrowing rate and the weighted average remaining lease term for all operating leases held by the Company were 5.21% and 11.1 years, respectively. Cash paid for lease liabilities was $4.5 million and $8.9 million during the three and six months ended June 30, 2022, respectively, compared to $4.4 million and $8.1 million during the three and six months ended June 30, 2021, respectively. The Company recorded operating lease expense of $4.2 million and $8.3 million during the three and six months ended June 30, 2022, respectively, as compared to $4.4 million and $8.6 million during the three and six months ended June 30, 2021, respectively.

18


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

 

10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2022

 

 

2021

 

Accounts payable

 

$

40,047

 

 

$

55,721

 

Accrued compensation

 

 

52,865

 

 

 

77,256

 

Accrued other

 

 

93,902

 

 

 

75,514

 

Total accounts payable and accrued expenses

 

$

186,814

 

 

$

208,491

 

 

A summary of the Company’s current provision for sales discounts, allowances and reserves is as follows:

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2022

 

 

2021

 

Medicaid rebates

 

$

191,458

 

 

$

195,413

 

Product discounts

 

 

13,956

 

 

 

14,951

 

Medicare Part D

 

 

13,087

 

 

 

14,348

 

Other

 

 

10,472

 

 

 

12,504

 

Total accrued sales discounts, allowances and reserves

 

$

228,973

 

 

$

237,216

 

 

11. LONG-TERM DEBT

Long-term debt consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2022

 

 

2021

 

2026 Term Loans, due March 12, 2026

 

$

294,537

 

 

$

295,804

 

Less: current portion

 

 

(3,000

)

 

 

(3,000

)

Long-term debt

 

$

291,537

 

 

$

292,804

 

 

In March 2021, the Company amended and refinanced its existing term loans, resulting in the 2026 Term Loans (such refinancing, the “Term Loan Refinancing”). The 2026 Term Loans mature on March 12, 2026 and bear interest payable at LIBOR plus 2.50% with a LIBOR floor of 0.5%. The 2026 Term Loans have an incremental facility capacity in the amount of $175.0 million plus additional amounts, provided that the Company meets certain conditions, including a specified leverage ratio. The Company was in compliance with its debt covenants at June 30, 2022.

 

Included in “Interest expense” in the accompanying condensed consolidated statement of operations and comprehensive (loss) income in the six months ended June 30, 2021 was $2.1 million related to the Term Loan Refinancing. Refer to Note 11, Long-Term Debt within the “Notes to Consolidated Financial Statements” in the Annual Report for a discussion on accounting for the Term Loan Refinancing.

12. SHARE-BASED COMPENSATION

The following table presents share-based compensation expense included in the accompanying condensed consolidated statements of operations and comprehensive (loss) income:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

(In thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Cost of goods manufactured and sold

 

$

2,401

 

 

$

2,683

 

 

$

4,783

 

 

$

4,861

 

Research and development

 

 

7,222

 

 

 

7,131

 

 

 

12,830

 

 

 

11,194

 

Selling, general and administrative

 

 

13,754

 

 

 

17,738

 

 

 

24,107

 

 

 

26,948

 

Total share-based compensation expense

 

$

23,377

 

 

$

27,552

 

 

$

41,720

 

 

$

43,003

 

19


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

 

At June 30, 2022 and December 31, 2021, $2.8 million and $2.3 million, respectively, of share-based compensation expense was capitalized and recorded as “Inventory” in the accompanying condensed consolidated balance sheets.

13. (LOSS) EARNINGS PER SHARE

Basic (loss) earnings per ordinary share is calculated based upon net (loss) income available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted (loss) earnings per ordinary share, the Company adjusts the weighted average number of ordinary shares outstanding for the effect of outstanding ordinary share equivalents such as stock options and restricted stock unit awards.

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

(In thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

$

(30,136

)

 

$

2,364

 

 

$

(66,039

)

 

$

(20,054

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of ordinary shares outstanding

 

 

163,839

 

 

 

160,817

 

 

 

163,165

 

 

 

160,229

 

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock options

 

 

 

 

 

461

 

 

 

 

 

 

 

Restricted stock unit awards

 

 

 

 

 

2,659

 

 

 

 

 

 

 

Dilutive ordinary share equivalents

 

 

 

 

 

3,120

 

 

 

 

 

 

 

Shares used in calculating diluted (loss) earnings per share

 

 

163,839

 

 

 

163,937

 

 

 

163,165

 

 

 

160,229

 

The following outstanding ordinary share equivalents were not included in the net (loss) earnings per ordinary share calculation because the effect would have been anti-dilutive:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

(In thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Stock options

 

 

12,781

 

 

 

15,465

 

 

 

12,677

 

 

 

15,265

 

Restricted stock unit awards

 

 

4,718

 

 

 

596

 

 

 

6,251

 

 

 

3,189

 

Total

 

 

17,499

 

 

 

16,061

 

 

 

18,928

 

 

 

18,454

 

 

14. INCOME TAXES

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In determining future taxable income, the Company is responsible for assumptions that it utilizes including the amount of Irish and non-Irish pre‑tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company uses to manage the underlying business.

The Company recorded income tax benefits of $3.1 million and $12.2 million during the three and six months ended June 30, 2022, respectively, which were primarily due to a change to Section 174 of the Tax Cuts and Jobs Act of 2017 (as amended, the “TCJA”), which became effective on January 1, 2022. Under the TCJA, the Company is required to capitalize, and subsequently amortize, R&D expenses over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S. The capitalization of R&D expenses during these periods resulted in an increase to the Company’s U.S. taxable income and foreign derived intangible income (“FDII”), resulting in a significant increase in the Company’s FDII deduction.

 

20


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

 

15. COMMITMENTS AND CONTINGENT LIABILITIES

Litigation

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company would accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on the Company’s best estimates, utilizing all available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company’s operating results. At June 30, 2022, there were no potential material losses from claims, asserted or unasserted, or legal proceedings that the Company determined were probable of occurring.

Janssen Arbitration Proceedings

In April 2022, Alkermes Pharma Ireland Limited commenced binding arbitration proceedings to settle, among other things, whether, notwithstanding Janssen Pharmaceutica’s partial termination of two license agreements with the Company, it has a continuing obligation to pay royalties on sales in the U.S. of INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA and CABENUVA, products developed under or enabled by these license agreements. The arbitration is to be conducted pursuant to the Institute for Conflict Prevention and Resolution (CPR) Rules for Non-Administered Arbitration. The request for arbitration seeks, among other remedies, a declaration that Janssen Pharmaceutica is in breach of the license agreements and a resumption of royalty payments for sales of the relevant products in the U.S.

INVEGA SUSTENNA ANDA Litigation

Janssen Pharmaceutica and Janssen Pharmaceuticals, Inc. initiated patent infringement lawsuits in the U.S. District Court for the District of New Jersey (the “NJ District Court”) in January 2018 against Teva Pharmaceuticals USA, Inc. (“Teva”) and Teva Pharmaceuticals Industries, Ltd. (“Teva PI”) (such lawsuit, the “Teva Lawsuit”), in August 2019 against Mylan Laboratories Limited (“Mylan Labs”) and other Mylan entities (the “Mylan Lawsuit”) and in December 2019 against Pharmascience, Inc. (“Pharmascience”), Mallinckrodt plc, and SpecGX LLC (the “Pharmascience Lawsuit”), and in the U.S. District Court for the District of Delaware in December 2021 against Tolmar Holding, Inc., Tolmar Pharmaceuticals, Inc., Tolmar Therapeutics, Inc., and Tolmar, Inc. (“Tolmar” and such lawsuit, the “Tolmar Lawsuit”), following the respective filings by each of Teva, Mylan Labs, Pharmascience and Tolmar of an Abbreviated New Drug Application (“ANDA”) seeking approval from the FDA to market a generic version of INVEGA SUSTENNA before the expiration of U.S. Patent No. 9,439,906. In October 2021, the NJ District Court entered a judgment in favor of the Janssen entities in the Teva Lawsuit. In December 2021, the NJ District Court entered a judgment in favor of the Janssen entities in the Mylan Lawsuit, based on the parties’ prior stipulation to be bound by the judgment in the Teva Lawsuit. The Teva entities and Mylan Labs each filed notices of appeal of their respective judgments with the U.S. Court of Appeals for the Federal Circuit, which were consolidated in January 2022. A trial was scheduled in the Tolmar Lawsuit for October 2023. The Pharmascience Lawsuit remains pending. The Company is not a party to any of these proceedings.

INVEGA TRINZA ANDA Litigation

In September 2020, Janssen Pharmaceutica, Janssen Pharmaceuticals, Inc., and Janssen Research & Development, LLC, initiated a patent infringement lawsuit in the NJ District Court against Mylan Labs, Mylan, and Mylan Institutional LLC following the filing by Mylan Labs of an ANDA seeking approval from the FDA to market a generic version of INVEGA TRINZA before the expiration of U.S. Patent No. 10,143,693. Requested judicial remedies include recovery of litigation costs and injunctive relief. A trial has been scheduled for October 2022. The Company is not a party to this proceeding.

VIVITROL ANDA Litigation

In September 2020, Alkermes, Inc. and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit in the NJ District Court against Teva and Teva PI following the filing by Teva of an ANDA seeking approval from the FDA to

21


ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

 

engage in the commercial manufacture, use or sale of a generic version of VIVITROL (naltrexone for extended-release injectable suspension) before the expiration of the Company’s U.S. Patent No. 7,919,499. Teva filed its answer in November 2020, which included counterclaims against the Company. The Company filed its reply to Teva’s counterclaims in December 2020. The Company intends to vigorously defend its IP. The filing of the lawsuit triggered a stay of FDA approval of the ANDA for up to 30 months in accordance with the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act).

Government Matters

The Company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL. The Company is cooperating with the investigations.

Product Liability and Other Legal Proceedings

 

The Company is involved in litigation and other legal proceedings incidental to its normal business activities, including product liability cases alleging that the FDA-approved VIVITROL labeling was inadequate and caused the users of the product to suffer from opioid overdose and death. The Company intends to vigorously defend itself in these matters. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing proceedings would have a material adverse effect on the Company’s business or financial condition.

 

22


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the accompanying condensed consolidated financial statements and related notes beginning on page 5 in this Form 10-Q, and “Part II, Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the audited financial statements and notes thereto accompanying our Annual Report.

Executive Summary

Net loss was $(30.1) million and $(66.0) million or $(0.18) and $(0.40) per ordinary share—basic and diluted, for the three and six months ended June 30, 2022, respectively, as compared to a net income of $2.4 million and a net loss of $(20.1) million or $0.01 and $(0.13) per ordinary share—basic and diluted for the three and six months ended June 30, 2021, respectively.

The increases in net loss in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to decreases of $57.0 million and $71.6 million, respectively, in manufacturing and royalty revenues, increases of $11.4 million and $48.6 million, respectively, in operating expenses, and decreases of $2.4 million and $22.7 million, respectively, in the fair value of our contingent consideration related to increased risk of non-payment, partially offset by increases of $30.0 million and $71.3 million, respectively, in product sales, net. The increases in operating expenses in the three and six months ended June 30, 2022 primarily related to increases of $5.2 million and $19.4 million, respectively, in cost of goods manufactured and sold and increases of $11.2 million and $31.1 million, respectively, in selling, general and administrative expense.

These items are discussed in greater detail later in the “Results of Operations” section in this “Part I, Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q.

COVID-19 Update

In March 2020, COVID-19 was declared a global pandemic by the World Health Organization. To date, COVID-19 has surfaced in nearly all regions around the world and resulted in travel restrictions and business slowdowns and/or shutdowns in affected areas. Ireland, all U.S. states, and many local jurisdictions and countries around the world have, at times during the pandemic, issued and implemented quarantines, vaccine and masking mandates, restrictive executive orders and other similar government orders, restrictions, and recommendations for their residents to help control the spread of COVID-19, and may continue to do so while the pandemic persists. Such orders, mandates, restrictions and/or recommendations, and/or the perception that additional orders, mandates, restrictions or recommendations could occur, have, at times during the pandemic, resulted in widespread interruptions and closures of businesses, including healthcare systems that serve people living with addiction and serious mental illness, work stoppages, slowdowns and/or delays, remote work policies and travel restrictions, among other effects.

The COVID-19 pandemic has caused, and we expect may continue to cause, varying degrees of disruption to our employees and our business operations. While we have continued to operate our manufacturing facilities and supply our medicines throughout the pandemic, we have, at times during the pandemic experienced labor or supply chain disruptions at our manufacturing facilities, and may continue to experience such disruptions while the pandemic persists. In addition, while we have continued to conduct R&D activities, including our ongoing clinical trials, the COVID-19 pandemic has at times impacted the timelines of certain of our early-stage discovery efforts and clinical trials, and may continue to impact such timelines while the pandemic persists. We work with our internal teams, our clinical investigators, R&D vendors and critical supply chain vendors to continually assess, and mitigate, the potential impact of COVID-19 on our manufacturing operations and R&D activities.

A number of the marketed products from which we derive revenue, including manufacturing and royalty revenue, are injectable medications administered by healthcare professionals. Given developments that have transpired to date, and may continue to transpire, in response to the pandemic, including business closures, travel restrictions, quarantine, testing and/or vaccine mandates and other protocols, labor shortages and other restrictive measures, commercial sales of these marketed products have been adversely impacted to varying degrees during the pandemic and may continue to be adversely impacted while the pandemic persists.

23


 

In addition, we rely upon third parties for many aspects of our business, including the provision of goods and services related to the manufacture of our clinical products and our and our partners’ marketed products, the conduct of our clinical trials, and the sale of our proprietary marketed products and the marketed products of our licensees from which we receive manufacturing and royalty revenue. Any prolonged material disruption to the third parties on which we rely could negatively impact our ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on our business, results of operations and financial condition.

Due to numerous uncertainties surrounding the ongoing COVID-19 pandemic, the actual impact of the pandemic on our financial condition and operating results may differ from our current projections. These uncertainties include, among other things, the ultimate severity and duration of the pandemic and the manner in which it continues to evolve, including the emergence, prevalence and severity of new or existing COVID-19 variants, and future developments in response thereto, which are highly uncertain and cannot be predicted as of the date of this Form 10-Q. For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, our financial condition or our results of operations, see “Part I, Item 1A—Risk Factors” in our Annual Report and specifically the section entitled “—Our business, financial condition and results of operations have been, and may continue to be, adversely affected by the ongoing COVID-19 pandemic or other similar outbreaks of contagious diseases.”

 

Products

Marketed Products

The key marketed products discussed below have generated, or are expected to generate, significant revenues for us. See the descriptions of the marketed products below and “Part I, Item 1A—Risk Factors” in our Annual Report for important factors that could adversely affect our marketed products. See the “Patents and Proprietary Rights” section in “Part I, Item 1—Business” in our Annual Report for information with respect to the IP protection for these marketed products.

 

24


 

 

The following provides summary information regarding our proprietary products that we commercialize:

 

Proprietary Products

 

 

 

 

 

 

 

Product

 

Indication(s)

 

 

Territory

 

 

 

 

 

 

 

Initiation or re-initiation of

ARISTADA for the treatment of

Schizophrenia

 

 

U.S.

 

Schizophrenia

 

 

U.S.

 

 

 

 

 

 

 

 

 

 

 

 

 

Schizophrenia and

Bipolar I disorder

 

 

 

U.S.

 

 

 

 

 

 

 

 

 

 

 

 

 

Alcohol

dependence and

Opioid dependence

 

 

U.S.

25


 

 

The following provides summary information regarding our key licensed product and certain key third-party products using our proprietary technologies under license, all of which are commercialized by our licensees:

 

Key Third-Party Products Using Our Proprietary Technologies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

Indication(s)

 

Licensee

 

Licensed Territory

 

 

 

 

 

 

 

RISPERDAL CONSTA

 

Schizophrenia

and Bipolar I

disorder

 

Janssen

Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (“Janssen International”)

 

 

Worldwide

 

 

 

 

 

 

 

INVEGA SUSTENNA* / XEPLION

 

INVEGA SUSTENNA:

Schizophrenia

and Schizoaffective

disorder

 

XEPLION:

Schizophrenia

 

Janssen Pharmaceutica 

(together with Janssen Pharmaceuticals, Inc., Janssen International and their affiliates “Janssen”)

 

 

Worldwide

 

 

INVEGA TRINZA* / TREVICTA

 

Schizophrenia

 

Janssen

 

Worldwide

 

INVEGA HAFYERA* / BYANNLI

 

Schizophrenia

 

Janssen

 

Worldwide

 

 

*

Janssen partially terminated its license agreement related to these products in the U.S., effective February 2022. See the section entitled “Products Using Our Proprietary Technologies” below and Note 15, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for more information with respect to this partial termination and the arbitration proceedings that we commenced related to such partial termination.

 

 

Our Key Licensed Product

 

Product

 

Indication(s)

 

Licensee

 

Licensed Territory

 

 

 

 

 

 

 

VUMERITY

 

Multiple sclerosis

 

Biogen

 

Worldwide

 

Proprietary Products

We have developed and now commercialize products designed to help address the unmet needs of people living with opioid dependence, alcohol dependence, schizophrenia and bipolar I disorder. See the “Patents and Proprietary Rights” section in “Part I, Item 1—Business” in our Annual Report for information with respect to the IP protection for our proprietary products.

26


 

ARISTADA

 

ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA utilizes our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is available in four dose strengths with once-monthly dosing options (441 mg, 662 mg and 882 mg), a six-week dosing option (882 mg) and a two-month dosing option (1064 mg). ARISTADA is packaged in a ready-to-use, pre-filled syringe product format. We exclusively manufacture and commercialize ARISTADA in the U.S.

ARISTADA INITIO

 

ARISTADA INITIO (aripiprazole lauroxil) leverages our proprietary LinkeRx and NanoCrystal technologies and provides an extended-release formulation of aripiprazole lauroxil in a smaller particle size compared to ARISTADA, thereby enabling faster dissolution and more rapid achievement of relevant levels of aripiprazole in the body. ARISTADA INITIO, combined with a single 30 mg dose of oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults. The first ARISTADA dose may be administered on the same day as the ARISTADA INITIO regimen or up to 10 days thereafter. We exclusively manufacture and commercialize ARISTADA INITIO in the U.S.

LYBALVI

 

LYBALVI (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is composed of olanzapine, an established antipsychotic agent, co-formulated with samidorphan, a new chemical entity, in a single bilayer tablet. LYBALVI was launched commercially in October 2021 and is available in fixed dosage strengths composed of 10 mg of samidorphan and 5 mg, 10 mg, 15 mg or 20 mg of olanzapine. We exclusively manufacture and commercialize LYBALVI in the U.S.

 

In June 2022, U.S. Patent No. 11,351,166 relating to LYBALVI was granted. The patent has claims to methods of treating schizophrenia or bipolar disorder and expires in 2031.

VIVITROL

 

VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the Commonwealth of Independent States for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We exclusively manufacture and commercialize VIVITROL in the U.S.

 

For a discussion of legal proceedings related to VIVITROL, see Note 15, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q, and for information about risks relating to such legal proceedings, see “Part I, Item 1A—Risk Factors” in our Annual Report and specifically the sections entitled “—Patent and other IP protection for our products is key to our business and our competitive position but is uncertain,” “—Uncertainty over IP in the biopharmaceutical industry has been the source of litigation, which is inherently costly and unpredictable, could significantly delay or prevent approval or negatively impact commercialization of our products, and could adversely affect our business” and “—Litigation or arbitration filed against Alkermes, including securities litigation, or actions (such as citizens petitions) filed against regulatory agencies in respect of our products, may result in financial losses, harm our reputation, divert management resources, negatively impact the approval of our products, or otherwise negatively impact our business.”

27


 

Licensed Products and Products Using Our Proprietary Technologies

We have licensed products to third parties for commercialization and have licensed our proprietary technologies to third parties to enable them to develop, commercialize and/or manufacture products. See the “Proprietary Technology Platforms” and “Patents and Proprietary Rights” sections in “Part I, Item 1—Business” in our Annual Report for information with respect to our proprietary technologies and the IP protection for these products. We receive royalties and/or manufacturing and other revenues from the commercialization of these products under our collaborative arrangements with these third parties. Such arrangements include the following:

Products Using Our Proprietary Technologies

 

INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI

 

In November 2021, we received notice of partial termination of our license agreement with Janssen in respect of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA pursuant to which Janssen received access and rights to Alkermes’ small particle pharmaceutical compound technology, known as NanoCrystal Technology. This partial termination became effective in February 2022. In April 2022, we commenced binding arbitration proceedings related to, among other things, Janssen’s partial termination of this license agreement and Janssen’s royalty and other obligations under the agreement. For additional information regarding the arbitration proceedings with Janssen, see Note 15, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q and for information about risks relating to this notice of partial termination and our collaborative arrangements more broadly, see “Part I, Item 1A—Risk Factors” in our Annual Report and specifically that section entitled “We rely heavily on our licensees in the commercialization and continued development of products from which we receive revenue and, if our licensees are not effective, or if disputes arise in respect of our contractual arrangements, our revenues could be materially adversely affected.”

 

The long-acting INVEGA products are long-acting atypical antipsychotics owned and commercialized worldwide by Janssen. We believe that these products were developed using, and incorporate, our technologies.

 

INVEGA SUSTENNA is approved in the U.S. for the treatment of schizophrenia and for the treatment of schizoaffective disorder as either a monotherapy or adjunctive therapy. Paliperidone palmitate extended-release injectable suspension is approved in the European Union (“EU”) and other countries outside of the U.S. for the treatment of schizophrenia and is marketed and sold under the trade name XEPLION. INVEGA SUSTENNA/XEPLION is manufactured by Janssen.

 

INVEGA TRINZA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months. TREVICTA is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION. INVEGA TRINZA/TREVICTA is manufactured by Janssen.

 

INVEGA HAFYERA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months or INVEGA TRINZA for at least three months. BYANNLI is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION or TREVICTA. INVEGA HAFYERA/BYANNLI is manufactured by Janssen.

 

For a discussion of legal proceedings related to certain of the patents covering INVEGA SUSTENNA and INVEGA TRINZA, see Note 15, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q and for information about risks relating to such legal proceedings, see “Part I, Item 1A—Risk Factors” in our Annual Report and specifically the section entitled “We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

 

28


 

 

RISPERDAL CONSTA

 

RISPERDAL CONSTA (risperidone long-acting injection) is a long-acting atypical antipsychotic owned and commercialized worldwide by Janssen that incorporates our proprietary technologies. RISPERDAL CONSTA is approved in the U.S. for the treatment of schizophrenia and as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA is approved in numerous countries outside of the U.S. for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one intramuscular injection every two weeks. RISPERDAL CONSTA microspheres are exclusively manufactured by us.

Licensed Product

 

VUMERITY

 

VUMERITY (diroximel fumarate) is a novel, oral fumarate with a distinct chemical structure that is approved in the U.S., the EU and several other countries for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

 

Under our license and collaboration agreement with Biogen, Biogen holds the exclusive, worldwide license to develop and commercialize VUMERITY. For more information about the license and collaboration agreement with Biogen, see the “Collaborative Arrangements—Biogen” section in “Part I, Item 1—Business” in our Annual Report.

Key Development Program

 

Our R&D is focused on the development of innovative medicines in the fields of neuroscience and oncology that are designed to address unmet patient needs. As part of our ongoing R&D efforts, we have devoted, and will continue to devote, significant resources to conducting preclinical work and clinical studies to advance the development of new pharmaceutical products. The discussion below highlights our current key development program. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in “Part I, Item 1A—Risk Factors” in our Annual Report. See the “Patents and Proprietary Rights” section in “Part I, Item 1—Business” in our Annual Report for information with respect to the IP protection for our key development program.

 

Nemvaleukin alfa

 

Nemvaleukin alfa (“nemvaleukin”) is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (“IL-2”) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

 

ARTISTRY is our clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous (“IV”) and subcutaneous (“SC”) dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. ARTISTRY-1 (evaluating IV nemvaleukin) and ARTISTRY-2 (evaluating SC nemvaleukin) are ongoing phase 1/2 studies evaluating the safety, tolerability, efficacy and pharmacokinetic and pharmacodynamic effects of nemvaleukin in patients with refractory advanced solid tumors, in both monotherapy and combination settings. ARTISTRY-3 is an ongoing phase 2 study evaluating the efficacy, safety and tolerability of less frequent dosing of IV nemvaleukin and pharmacokinetic and pharmacodynamic effects of IV nemvaleukin in the tumor microenvironment as a monotherapy and in combination with pembrolizumab in a variety of advanced solid tumors. ARTISTRY-6 is an ongoing phase 2 study evaluating the anti-tumor activity, safety and tolerability of IV nemvaleukin monotherapy in patients with mucosal melanoma and SC nemvaleukin monotherapy in patients with advanced cutaneous melanoma. ARTISTRY-7 is an ongoing phase 3 study evaluating the efficacy, safety and tolerability of IV nemvaleukin as monotherapy and in combination with pembrolizumab compared to investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer.

29


 

 

In March 2021 and August 2021, we announced that the FDA granted Orphan Drug Designation and Fast Track designation, respectively, to nemvaleukin for the treatment of mucosal melanoma. In October 2021, we announced that the FDA granted Fast Track designation to nemvaleukin in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer.

Results of Operations

 

Product Sales, Net

Our product sales, net, consist of sales of VIVITROL, ARISTADA and ARISTADA INITIO, and, following its commercial launch in the U.S. in October 2021, LYBALVI, primarily to wholesalers, specialty distributors and pharmacies. The following table presents the adjustments deducted from product sales, gross to arrive at product sales, net, for sales of VIVITROL, ARISTADA, ARISTADA INITIO and LYBALVI during the three and six months ended June 30, 2022 and 2021:

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

June 30,

 

 

(In millions, except for % of Sales)

2022

 

 

% of Sales

 

 

 

2021

 

 

% of Sales

 

 

 

2022

 

 

% of Sales

 

 

 

2021

 

 

% of Sales

 

 

Product sales, gross

$

386.8

 

 

 

100.0

 

%

 

$

343.5

 

 

 

100.0

 

%

 

$

729.2

 

 

 

100.0

 

%

 

$

616.1

 

 

 

100.0

 

%

Adjustments to product sales, gross:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medicaid rebates

 

(88.7

)

 

 

(22.9

)

%

 

 

(88.1

)

 

 

(25.6

)

%

 

 

(165.2

)

 

 

(22.7

)

%

 

 

(159.0

)

 

 

(25.8

)

%

Chargebacks

 

(41.5

)

 

 

(10.7

)

%

 

 

(33.7

)

 

 

(9.8

)

%

 

 

(75.3

)

 

 

(10.3

)

%

 

 

(58.7

)

 

 

(9.5

)

%

Product discounts

 

(30.8

)

 

 

(8.0

)

%

 

 

(28.4

)

 

 

(8.3

)

%

 

 

(57.7

)

 

 

(7.9

)

%

 

 

(49.8

)

 

 

(8.1

)

%

Medicare Part D

 

(16.5

)

 

 

(4.3

)

%

 

 

(16.8

)

 

 

(4.9

)

%

 

 

(32.5

)

 

 

(4.5

)

%

 

 

(29.9

)

 

 

(4.9

)

%

Other

 

(18.5

)

 

 

(4.8

)

%

 

 

(15.7

)

 

 

(4.6

)

%

 

 

(36.4

)

 

 

(4.9

)

%

 

 

(27.9

)

 

 

(4.5

)

%

Total adjustments

 

(196.0

)

 

 

(50.7

)

%

 

 

(182.7

)

 

 

(53.2

)

%

 

 

(367.1

)

 

 

(50.3

)

%

 

 

(325.3

)

 

 

(52.8

)

%

Product sales, net

$

190.8

 

 

 

49.3

 

%

 

$

160.8

 

 

 

46.8

 

%

 

$

362.1

 

 

 

49.7

 

%

 

$

290.8

 

 

 

47.2

 

%

 

The following table compares product sales, net revenues earned during the three and six months ended June 30, 2022 and 2021:

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

June 30,

 

 

 

 

 

(In millions)

2022

 

 

2021

 

 

Change

 

 

2022

 

 

2021

 

 

Change

 

VIVITROL

$

96.1

 

 

$

88.4

 

 

$

7.7

 

 

$

181.0

 

 

$

163.0

 

 

$

18.0

 

ARISTADA and ARISTADA INITIO

 

74.6

 

 

 

72.4

 

 

 

2.2

 

 

 

147.1

 

 

 

127.8

 

 

 

19.3

 

LYBALVI

 

20.1

 

 

 

 

 

 

20.1

 

 

 

34.0

 

 

 

 

 

 

34.0

 

Product sales, net

$

190.8

 

 

$

160.8

 

 

$

30.0

 

 

$

362.1

 

 

$

290.8

 

 

$

71.3

 

 

VIVITROL product sales, gross, increased by 7% and 8% during the three and six months ended June 30, 2022, respectively, primarily due to increases of 1% and 4%, respectively, in the number of VIVITROL units sold and a 6% increase in the selling price of VIVITROL that went into effect in April 2022. ARISTADA and ARISTADA INITIO product sales, gross, increased by 2% and 14% during the three and six months ended June 30, 2022, respectively, primarily due to a 3% increase in the selling price of ARISTADA and ARISTADA INITIO that went into effect in April 2022. In addition, in the six months ended June 30, 2022, there was an 11% increase, as compared to the six months ended June 30, 2021, in the number of ARISTADA units sold.

 

The decreases in Medicaid rebates as a percentage of sales during the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to actual Medicaid utilization rates being lower than original estimates as such rates began to normalize from pandemic levels. The increases in chargebacks as a percentage of sales during the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to the increases in selling price of VIVITROL and ARISTADA, as described above, and increased utilization of certain federal government programs related to VIVITROL.

30


 

Manufacturing and Royalty Revenues

The following table compares manufacturing and royalty revenues earned during the three and six months ended June 30, 2022 and 2021:

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

June 30,

 

 

 

 

 

(In millions)

2022

 

 

2021

 

 

Change

 

 

2022

 

 

2021

 

 

Change

 

Manufacturing and royalty revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-acting INVEGA products

$

26.6

 

 

$

81.0

 

 

$

(54.4

)

 

$

63.7

 

 

$

142.6

 

 

$

(78.9

)

VUMERITY

 

26.2

 

 

 

20.4

 

 

 

5.8

 

 

 

56.8

 

 

 

33.8

 

 

 

23.0

 

RISPERDAL CONSTA

 

10.4

 

 

 

14.4

 

 

 

(4.0

)

 

 

27.8

 

 

 

28.6

 

 

 

(0.8

)

Other

 

22.1

 

 

 

26.5

 

 

 

(4.4

)

 

 

42.2

 

 

 

57.1

 

 

 

(14.9

)

Manufacturing and royalty revenues

$

85.3

 

 

$

142.3

 

 

$

(57.0

)

 

$

190.5

 

 

$

262.1

 

 

$

(71.6

)

 

Our agreements with Janssen related to the long-acting INVEGA products provide for tiered royalty payments, which consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5% on calendar year net sales up to $250 million; 5.5% on calendar year net sales of between $250 million and $500 million; and 7.5% on calendar year net sales exceeding $500 million. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from the first commercial sale of a product in each individual country.

 

The decreases in royalty revenues from the long-acting INVEGA products during the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to the partial termination of our license agreement with Janssen related to such products. When the partial termination of the license agreement became effective in February 2022, we stopped recognizing royalty revenue related to net sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA in the U.S. During the three and six months ended June 30, 2022, Janssen’s rest of world net sales were $362.0 million and $749.0 million, respectively, as compared to $380.0 million and $756.0 million during the three and six months ended June 30, 2021, respectively.

We expect royalty revenues from net sales of XEPLION, TREVICTA and BYANNLI to decrease over time. The amount and timing of royalty revenues from sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA depend upon the outcome of our dispute with Janssen related to the basis for its partial termination of our license agreement in respect of these products. In November 2021, we received notice of partial termination of our license agreement with Janssen in respect of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA pursuant to which Janssen received access and rights to Alkermes’ small particle pharmaceutical compound technology, known as NanoCrystal Technology. When the partial termination became effective in February 2022, Janssen ceased paying royalties related to sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA in the U.S. and the Company stopped recognizing royalty revenue related to net sales of these products. In April 2022, we commenced binding arbitration proceedings related to, among other things, Janssen’s partial termination of this license agreement and Janssen’s royalty and other obligations under the agreement. For additional information regarding the arbitration proceedings with Janssen, see Note 15, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q. For more information about the license agreement with Janssen in respect of the long-acting INVEGA products, see the “Collaborative Arrangements—Janssen” section in “Part I, Item 1—Business” in our Annual Report. For information about risks relating to the notice of partial termination and our collaborative arrangements more broadly, see “Part I, Item 1A—Risk Factors” in our Annual Report and specifically that section entitled “We rely heavily on our licensees in the commercialization and continued development of products from which we receive revenue and, if our licensees are not effective, or if disputes arise in respect of our contractual arrangements, our revenues could be materially adversely affected.”

In addition, each of INVEGA SUSTENNA and INVEGA TRINZA are currently subject to Paragraph IV litigation in response to companies seeking to market generic versions of such products. Increased competition from new products or generic versions of these products may lead to reduced unit sales of such products and increased pricing pressure. For a discussion of these legal proceedings, see Note 15, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q and for information about risks relating to these legal proceedings, see “Part I, Item 1A—Risk Factors” in our Annual Report, and specifically the section entitled “We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

31


 

We recognize manufacturing revenue for RISPERDAL CONSTA at the point in time when RISPERDAL CONSTA has been fully manufactured, which is deemed to have occurred when the product is approved for shipment by both us and Janssen. We record royalty revenue, equal to 2.5% of Janssen’s end-market net sales, in the period that the end-market sale of RISPERDAL CONSTA occurs. The decrease in revenue from RISPERDAL CONSTA during the three months ended June 30, 2022, as compared to the three months ended June 30, 2021, was primarily due to a decrease of $3.4 million in manufacturing revenue and a decrease of $0.6 million in royalty revenue. The decrease in revenue from RISPERDAL CONSTA during the six months ended June 30, 2022, as compared to the six months ended June 30, 2021, was primarily due to a $2.3 million decrease in royalty revenue, partially offset by a $1.5 million increase in manufacturing revenue. The decrease in manufacturing revenue during the three months ended June 30, 2022, as compared to the three months ended June 30, 2021, was primarily due to a decrease in our manufacturing fee. Pursuant to the terms of our manufacturing and supply agreement with Janssen, our manufacturing fee decreases as forecasted manufacturing production increases. Based on Janssen’s anticipated volume increases, our manufacturing fee decreased from 8.6% to 7.9% of Janssen’s net unit sales price. This decrease was partially offset by an increase in shipments to Janssen during the three months ended June 30, 2022, as compared to the three months ended June 30, 2021. The increase in manufacturing revenue during the six months ended June 30, 2022, as compared to the six months ended June 30, 2021 was primarily due to an increase in the number of units approved for shipment to Janssen, partially offset by the decrease in our manufacturing fee, as noted above. The decreases in royalty revenue in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were due to decreases in end-market sales of RISPERDAL CONSTA, which were $125.0 million and $254.0 million during the three and six months ended June 30, 2022, respectively, as compared to $155.0 million and $312.0 million during the three and six months ended June 30, 2021, respectively.

We expect revenues from RISPERDAL CONSTA to decrease over time. The latest to expire patent covering RISPERDAL CONSTA expired in 2021 in the EU and will expire in 2023 in the U.S., and we are aware of potential generic competition for RISPERDAL CONSTA that may lead to reduced unit sales and increased pricing pressure.

We receive a 15% royalty on worldwide net sales of VUMERITY. We also recognize manufacturing revenue related to VUMERITY at cost plus 15%, upon release for bulk batches of VUMERITY and upon shipment for packaged lots of VUMERITY. The increases in revenue from VUMERITY during the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to increases in royalty revenue. Royalty revenue increased by $6.9 million and $15.1 million in the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. Net sales of VUMERITY were $136.8 million and $264.8 million during the three and six months ended June 30, 2022, respectively, as compared to $90.8 million and $164.1 million during the three and six months ended June 30, 2021, respectively. Manufacturing revenue increased by $7.9 million in the six months ended June 30, 2022, as compared to the six months ended June 30, 2021, due to an increase in the number of packaged batches that were manufactured for Biogen. Manufacturing revenue decreased by $1.1 million in the three months ended June 30, 2022, as compared to the three months ended June 30, 2021, primarily due to the manufacture of fewer commercial batches, as we work with Biogen and one of its suppliers to address a manufacturing issue, which, if it persists, will continue to negatively impact our manufacturing revenue and may negatively impact our royalty revenues.

Costs and Expenses

Cost of Goods Manufactured and Sold

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

June 30,

 

 

 

 

 

(In millions)

2022

 

 

2021

 

 

Change

 

 

2022

 

 

2021

 

 

Change

 

Cost of goods manufactured and sold

$

58.4

 

 

$

53.1

 

 

$

5.3

 

 

$

113.5

 

 

$

94.1

 

 

$

19.4

 

The increases in cost of goods manufactured and sold in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to increases of $1.4 million and $8.0 million, respectively, in the cost of goods manufactured for VUMERITY and increases of $5.1 million and $6.9 million, respectively, in the cost of goods sold for LYBALVI. In addition, in the six months ended June 30, 2022, there was an increase of $3.2 million, as compared to the six months ended June 30, 2021, in the cost of goods manufactured for RISPERDAL CONSTA. These increases were all related to an increase in the number of units manufactured and sold for each of these products, as discussed above.

32


 

Research and Development Expenses

For each of our R&D programs, we incur both external and internal expenses. External R&D expenses include fees for clinical and non-clinical activities performed by contract research organizations, consulting fees, and costs related to laboratory services, the purchase of drug product materials and third-party manufacturing development activities. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. We track external R&D expenses for each of our development programs; however, internal R&D expenses are not tracked by individual program as they can benefit multiple programs or our technologies in general.

The following table sets forth our external R&D expenses for the three and six months ended June 30, 2022 and 2021 relating to our then current development programs and our internal R&D expenses, listed by the nature of such expenses:

 

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

June 30,

 

 

 

 

 

(In millions)

 

2022

 

 

2021

 

 

Change

 

 

2022

 

 

2021

 

 

Change

 

External R&D expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Development programs:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

nemvaleukin

 

$

17.1

 

 

$

22.7

 

 

$

(5.6

)

 

$

36.6

 

 

$

41.3

 

 

$

(4.7

)

LYBALVI

 

 

3.4

 

 

 

7.7

 

 

 

(4.3

)

 

 

9.2

 

 

 

14.5

 

 

 

(5.3

)

ALKS 1140

 

 

0.6

 

 

 

1.0

 

 

 

(0.4

)

 

 

2.3

 

 

 

2.3

 

 

 

 

Other external R&D expenses

 

 

18.0

 

 

 

14.0

 

 

 

4.0

 

 

 

33.7

 

 

 

28.1

 

 

 

5.6

 

Total external R&D expenses

 

 

39.1

 

 

 

45.4

 

 

 

(6.3

)

 

 

81.8

 

 

 

86.2

 

 

 

(4.4

)

Internal R&D expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee-related

 

 

40.6

 

 

 

38.9

 

 

 

1.7

 

 

 

80.7

 

 

 

76.8

 

 

 

3.9

 

Occupancy

 

 

4.5

 

 

 

5.0

 

 

 

(0.5

)

 

 

8.7

 

 

 

9.8

 

 

 

(1.1

)

Depreciation

 

 

2.9

 

 

 

2.9

 

 

 

 

 

 

5.7

 

 

 

6.3

 

 

 

(0.6

)

Other

 

 

5.7

 

 

 

5.2

 

 

 

0.5

 

 

 

11.9

 

 

 

10.6

 

 

 

1.3

 

Total internal R&D expenses

 

 

53.7

 

 

 

52.0

 

 

 

1.7

 

 

 

107.0

 

 

 

103.5

 

 

 

3.5

 

Research and development expenses

 

$

92.8

 

 

$

97.4

 

 

$

(4.6

)

 

$

188.8

 

 

$

189.7

 

 

$

(0.9

)

These amounts are not necessarily predictive of future R&D expenses. In an effort to allocate our spending most effectively, we continually evaluate our products under development, based on the performance of such products in preclinical and/or clinical trials, our expectations regarding the likelihood of their regulatory approval and our view of their future potential commercial viability, among other factors.

The decreases in expenses related to nemvaleukin in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to decreased spend on the ARTISTRY-1 and ARTISTRY-2 studies, partially offset by increased clinical spend on the ARTISTRY-7 study. For details on the ARTISTRY development program, see the “Key Development Program” section of this “Part I, Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q. The decreases in expenses related to LYBALVI in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to decreased R&D activities for the product in light of its commercial launch in October 2021. The increases in other external R&D expenses in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to increases of $1.2 million and $4.6 million, respectively, related to our early-stage development programs.

The increases in employee-related expense in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily related to increases of $1.3 million and $2.0 million, respectively, in labor and benefits, primarily due to increases in recruitment costs and temporary labor, and increases of $0.1 million and $1.7 million, respectively, in R&D-related share-based compensation expense.

33


 

Selling, General and Administrative Expense

 

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

June 30,

 

 

 

 

 

(In millions)

 

2022

 

 

2021

 

 

Change

 

 

2022

 

 

2021

 

 

Change

 

Selling and marketing expense

 

$

95.3

 

 

$

85.7

 

 

$

9.6

 

 

$

191.5

 

 

$

165.4

 

 

$

26.1

 

General and administrative expense

 

 

55.0

 

 

 

53.5

 

 

 

1.5

 

 

 

103.9

 

 

 

99.0

 

 

 

4.9

 

Selling, general and administrative expense

 

$

150.3

 

 

$

139.2

 

 

$

11.1

 

 

$

295.4

 

 

$

264.4

 

 

$

31.0

 

 

The increases in selling and marketing expense in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to increases in marketing expenses of $4.2 million and $7.9 million, respectively, and increases in professional service fees of $2.3 million and $4.7 million, respectively, in each case primarily due to commercial launch activities for LYBALVI, and increases in employee-related expenses of $2.4 million and $10.2 million, respectively, primarily due to a 7% increase in selling and marketing headcount from June 30, 2021 to June 30, 2022 in support of the launch of LYBALVI.

 

The increases in general and administrative expense in the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, were primarily due to increases in professional service fees of $5.3 million and $7.3 million, respectively, partially offset by decreases in general and administrative-related share-based compensation expense of $3.6 million and $3.7 million, respectively.

Other (Expense) Income, Net

 

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

June 30,

 

 

 

 

 

(In millions)

 

2022

 

 

2021

 

 

Change

 

 

2022

 

 

2021

 

 

Change

 

Interest income

 

$

0.9

 

 

$

0.6

 

 

$

0.3

 

 

$

1.5

 

 

$

1.5

 

 

$

 

Interest expense

 

 

(2.3

)

 

 

(2.4

)

 

 

0.1

 

 

 

(4.7

)

 

 

(6.4

)

 

 

1.7

 

Change in the fair value of contingent consideration

 

 

0.9

 

 

 

3.2

 

 

 

(2.3

)

 

 

(18.2

)

 

 

4.5

 

 

 

(22.7

)

Other income (expense), net

 

 

1.7

 

 

 

(0.2

)

 

 

1.9

 

 

 

4.2

 

 

 

(0.6

)

 

 

4.8

 

Total other (expense) income, net

 

$

1.2

 

 

$

1.2

 

 

$

 

 

$

(17.2

)

 

$

(1.0

)

 

$

(16.2

)

 

The increase in total other (expense) income, net in the six months ended June 30, 2022, as compared to the six months ended June 30, 2021, was primarily due to the change in the fair value of contingent consideration as a result of an increase in the risk of non-payment of future cash flows. The reasons for the increase in the risk of non-payment and the valuation approach used to determine the fair value of the contingent consideration are discussed in greater detail in Note 5, Fair Value, in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q. This was partially offset by a $2.1 million decrease in interest expense due to certain financing costs related to the Term Loan Refinancing completed in March 2021 and proceeds received in connection with the Fountain transaction in March 2022. The Term Loan Refinancing is discussed in Note 11, Long-Term Debt in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q. The Fountain transaction is discussed in Note 4, Investments, in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q.

Income Tax (Benefit) Provision

 

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

June 30,

 

 

 

 

 

(In millions)

 

2022

 

 

2021

 

 

Change

 

 

2022

 

 

2021

 

 

Change

 

Income tax (benefit) provision

 

$

(3.1

)

 

 

3.3

 

 

$

(6.4

)

 

$

(12.2

)

 

$

7.1

 

 

$

(19.3

)

 

The income tax (benefit) provision in the three months ended June 30, 2022 and 2021, respectively, primarily related to U.S. federal and state taxes. The favorable change in the income tax (benefit) provision was primarily due to an enhanced FDII deduction as a result of a change to Section 174 of the TCJA in relation to capitalization and amortization of R&D expenses. The income tax (benefit) in the six months ended June 30, 2022 was primarily due to the enhanced FDII deduction. The FDII deduction is discussed in Note 14, Income Taxes in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q. The income tax provision in the six months ended June 30, 2021 primarily related to a $6.6 million discrete tax expense related to employee equity activity.

 

34


 

 

Liquidity and Financial Condition

Our financial condition is summarized as follows:

 

 

 

June 30, 2022

 

 

December 31, 2021

 

(In millions)

 

U.S.

 

 

Ireland

 

 

Total

 

 

U.S.

 

 

Ireland

 

 

Total

 

Cash and cash equivalents

 

$

150.1

 

 

$

104.5

 

 

$

254.6

 

 

$

88.6

 

 

$

248.9

 

 

$

337.5

 

Investments—short-term

 

 

170.4

 

 

 

155.9

 

 

 

326.3

 

 

 

144.5

 

 

 

54.3

 

 

 

198.8

 

Investments—long-term

 

 

106.9

 

 

 

72.1

 

 

 

179.0

 

 

 

163.0

 

 

 

66.4

 

 

 

229.4

 

Total cash and investments

 

$

427.4

 

 

$

332.5

 

 

$

759.9

 

 

$

396.1

 

 

$

369.6

 

 

$

765.7

 

Outstanding borrowings—short and long-term

 

$

294.5

 

 

$

 

 

$

294.5

 

 

$

295.8

 

 

$

 

 

$

295.8

 

 

At June 30, 2022 our investments consisted of the following:

 

 

 

 

 

 

 

Gross

 

 

 

 

 

 

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Allowance for

 

 

Estimated

 

(In millions)

 

Cost

 

 

Gains

 

 

Losses

 

 

Credit Losses

 

 

Fair Value

 

Investments—short-term available-for-sale

 

$

329.5

 

 

$

 

 

$

(3.2

)

 

$

 

 

$

326.3

 

Investments—long-term available-for-sale

 

 

183.0

 

 

 

 

 

 

(5.8

)

 

 

 

 

 

177.2

 

Investments—long-term held-to-maturity

 

 

1.8

 

 

 

 

 

 

 

 

 

 

 

 

1.8

 

Total

 

$

514.3

 

 

$

 

 

$

(9.0

)

 

$

 

 

$

505.3

 

 

Sources and Uses of Cash

We generated $19.4 million and used $12.1 million of cash from operating activities during the six months ended June 30, 2022 and 2021, respectively. We expect that our existing cash, cash equivalents and investments will be sufficient to finance our anticipated working capital and other cash requirements, such as capital expenditures and principal and interest payments on our long‑term debt, for at least the twelve months following the date from which our financial statements were issued. Subject to market conditions, interest rates and other factors, we may pursue opportunities to obtain additional financing in the future, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets or other financing methods or structures. In addition, the 2026 Term Loans have an incremental facility capacity in an amount of $175.0 million, plus additional potential amounts, provided that we meet certain conditions, including a specified leverage ratio.

 

Our investment objectives are, first, to preserve liquidity and conserve capital and, second, to generate investment income. We mitigate credit risk in our cash reserves by maintaining a well-diversified portfolio that limits the amount of investment exposure as to institution, maturity and investment type. However, the value of these securities may be adversely affected by the instability of the global financial markets, which could, in turn, adversely impact our financial position and our overall liquidity. Our available-for-sale investments consist primarily of short and long-term U.S. government and agency debt securities, corporate debt securities and debt securities issued and backed by non-U.S. governments. Our held-to-maturity investments consist of investments that are held as collateral under certain letters of credit related to certain of our lease agreements.

 

We classify available‑for‑sale investments in an unrealized loss position that do not mature within twelve months as long‑term investments. We have the intent and ability to hold these investments until recovery, which may be at maturity, and it is more‑likely‑than‑not that we would not be required to sell these securities before recovery of their amortized cost. At June 30, 2022, we performed an analysis of our investments with unrealized losses for impairment and determined that they were not impaired.

 

We have no off-balance sheet arrangements that are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources in the next twelve months.

35


 

The following table summarizes our cash flows for the six months ended June 30, 2022 and 2021:

 

 

 

Six Months Ended June 30,

 

(In millions)

 

2022

 

 

2021

 

Cash and cash equivalents, beginning of period

 

$

337.5

 

 

$

273.0

 

Cash flows provided by (used in) operating activities

 

 

19.4

 

 

 

(12.1

)

Cash flows used in investing activities

 

 

(101.2

)

 

 

(33.8

)

Cash flows (used in) provided by financing activities

 

 

(1.1

)

 

 

31.2

 

Cash and cash equivalents, end of period

 

$

254.6

 

 

$

258.3

 

 

Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net loss for non-cash operating items such as depreciation, amortization and share-based compensation and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations.

The change in cash flows from operating activities was primarily due to an increase in cash provided by working capital, offset by an increase in our net loss, net of adjustments to reconcile net loss to cash flows from operating activities. The increase in cash from working capital was primarily related to an increase in cash flows from accounts receivable and decreases in cash flows used in inventory and accounts payable and accrued expenses, partially offset by increases in cash flows used for contract assets, prepaid expenses and other current assets and contract liabilities.

The increase in cash flows used in investing activities was primarily due to a $58.7 million increase in net purchase of investments, a $6.8 million decrease in payments received in connection with the contingent consideration resulting from the Gainesville Transaction and a $3.2 million increase in capital expenditures.

The change in cash flows from financing activities was primarily due to $23.6 million in proceeds from the Term Loan Refinancing, which we received in the six months ended June 30, 2021, and a $9.0 million decrease in the amount of cash that we received upon exercises of employee stock options, net of employee taxes.

Debt

At June 30, 2022, the principal balance of our borrowings consisted of $296.3 million outstanding under our 2026 Term Loans. See Note 11, Long-Term Debt, in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for further discussion of our 2026 Term Loans.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates under different conditions or using different assumptions. See the “Critical Accounting Estimates” section in “Part II, Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report for a discussion of our critical accounting estimates.

In relation to our contingent consideration, in light of Baudax’s disclosures regarding its ability to continue as a going concern, in March 2022 we increased our assessment of the likelihood that Baudax would default on its obligations to us to 100% from our prior determined likelihood of 55% as of December 31, 2021, and adjusted the recovery rate to 9% in March 2022 from 18% as of December 31, 2021. For further information regarding the calculation of the fair value of this contingent consideration, refer to Note 5, Fair Value in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q.

36


 

New Accounting Standards

See the “New Accounting Pronouncements” section in Note 2, Summary of Significant Accounting Policies in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for discussion of certain recent accounting standards applicable to us.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risks related to our investment portfolio, and the ways we manage such risks, are summarized in “Part II, Item 7A—Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report. We regularly review our marketable securities holdings and shift our investment holdings to those that best meet our investment objectives, which are to preserve capital, provide sufficient liquidity to satisfy operating requirements and generate investment income. Apart from such adjustments to our investment portfolio, there have been no material changes to our market risks since December 31, 2021, and we do not anticipate any near-term changes in the nature of our market risk exposures or in our management’s objectives and strategies with respect to managing such exposures.

We are exposed to non-U.S. currency exchange risk related to manufacturing and royalty revenues that we receive on certain of our products, partially offset by certain operating costs arising from expenses and payables in connection with our Irish operations that are settled predominantly in Euro. These non-U.S. currency exchange rate risks are summarized in “Part II, Item 7A—Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report. There has been no material change in our assessment of our sensitivity to non-U.S. currency exchange rate risk since December 31, 2021.

Item 4. Controls and Procedures

a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of June 30, 2022. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that our disclosure controls and procedures were effective as of June 30, 2022 to provide reasonable assurance that the information required to be disclosed by us in the reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

b) Change in Internal Control Over Financial Reporting

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37


 

PART II. OTHER INFORMATION

For information regarding legal proceedings, see the discussion of legal proceedings in Note 15, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q, which discussion is incorporated into this Part II, Item 1 by reference.

Item 1A. Risk Factors

For a discussion of our risk factors, see “Part I, Item 1A—Risk Factors” in our Annual Report. There have been no material changes from the risk factors disclosed in our Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On September 16, 2011, our board of directors authorized the continuation of the Alkermes, Inc. program to repurchase up to $215.0 million of our ordinary shares at the discretion of management from time to time in the open market or through privately negotiated transactions. We did not purchase any shares under this program during the six months ended June 30, 2022. As of June 30, 2022, we had purchased a total of 8,866,342 shares under this program at an aggregate cost of $114.0 million.

During the three months ended June 30, 2022, we acquired 18,566 of our ordinary shares, at an average price of $27.69 per share, to satisfy withholding tax obligations related to the vesting of employee equity awards.

Item 5. Other Information

Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans in accordance with Rule 10b5-1 under the Exchange Act. During the three months ended June 30, 2022, each of Dr. Craig C. Hopkinson and Mr. C. Todd Nichols, executive officers of the Company, and Mr. David W. Anstice AO, a former director of the Company, entered into a trading plan in accordance with Rule 10b5-1 and our policy governing transactions in our securities by our directors, officers and employees. We undertake no obligation to update or revise the information provided herein, including for any revision or termination of an established trading plan.

38


 

Item 6. Exhibits

The following exhibits are filed or furnished as part of this Form 10-Q:

EXHIBIT INDEX

 

Exhibit No.

 

Description of Exhibit

  3.1 #

 

Memorandum and Articles of Association of Alkermes plc, as amended on May 13, 2022.

  10.1

 

Alkermes plc 2018 Stock Option and Incentive Plan, as amended (incorporated by reference from Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) filed on July 7, 2022).

  10.1.1 #†

 

Form of Non-Employee Director New Director Grant Non-Qualified Stock Option Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.

  10.1.2 #†

 

Form of Non-Employee Director New Director Grant Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.

  31.1 #

 

Rule 13a-14(a)/15d-14(a) Certification.

  31.2 #

 

Rule 13a-14(a)/15d-14(a) Certification.

  32.1 ‡

 

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  101.SCH #

 

Inline XBRL Taxonomy Extension Schema Document.

  101.CAL #

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

  101.LAB #

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

  101.PRE #

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

  101.DEF #

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

  104 #

 

Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

 

#

Filed herewith.

Furnished herewith.

Indicates a management contract or any compensatory plan, contract or arrangement.

39


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

ALKERMES PLC

 

 

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

By:

/s/ Richard F. Pops

 

 

 

Richard F. Pops

 

 

 

Chairman and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

 

 

By:

/s/ Iain M. Brown

 

 

 

Iain M. Brown

 

 

 

Senior Vice President, Chief Financial Officer

 

 

 

(Principal Financial Officer and Principal Accounting Officer)

 

 

Date: July 27, 2022

 

40